What would you like to find today?

Disordered eating (a broad category of persistent, harmful patterns in eating or weight control) affects between 5% and 22% of children and adolescents worldwide, with similar rates seen in the United States. The consequences are far-reaching: these conditions are linked to bone fractures, anemia, malnutrition, dental erosion, obesity, diabetes, hypertension, and elevated cholesterol and triglycerides. They also carry one of the highest mortality rates of any psychiatric illness. 

Eating disorders rarely occur in isolation. They frequently arise alongside other psychiatric and neurological conditions. Yet, until now, no large-scale study had examined these co-occurrences in a nationally representative U.S. sample. A new study addresses that gap, focusing on children and adolescents aged 6–17 and the conditions most commonly associated with disordered eating, including ADHD. 

The Study: 

Researchers drew on data from the 2022–2023 National Survey of Children's Health (NSCH), a nationally representative, cross-sectional survey covering all 50 states and Washington, D.C. Households were selected using stratified, address-based sampling, and parents or guardians completed surveys about one randomly selected child per household. The final sample included 68,000 children and adolescents. 

Results: 

After accounting for factors including sex, age, race and ethnicity, household income, educational attainment, insurance status, and household language, children and adolescents with ADHD were 2.6 times more likely to have some form of disordered eating compared to their typically developing peers. 

The elevated risk appeared across a range of specific behaviors: 

• 60% more likely to over-exercise 

• Twice as likely to experience a fear of vomiting or choking 

• 2.4 times more likely to be extremely selective eaters, to skip meals, or to fast 

• 2.7 times more likely to purge food or vomit 

• 3 times more likely to show little interest in food 

• 3.2 times more likely to binge eat 

A greater tendency toward using diet pills, laxatives, or diuretics was also observed in the ADHD group, though this finding did not reach statistical significance. 

The Take-Away: 

These findings underscore a need to improve both prevention and treatment strategies for disordered eating, particularly in children and adolescents who have ADHD. Clinicians working with this population are advised to screen for a wide spectrum of disordered eating behaviors.

‍

‍

The Background:

For centuries, we’ve called the eyes the "windows to the soul," but for modern neurologists, they are quite literally a window into the brain. The retina and the central nervous system share the same embryonic origins, developing from the same neural tissue in the womb. Because of this deep biological connection, the back of your eye acts as a non-invasive map of your brain's health, displaying a complex web of nerves and blood vessels that can (theoretically!) mirror certain neurodevelopmental conditions. 

‍

Recently, a buzz rippled through the mental health community when a study published in partnership with Seoul National University Bundang Hospital claimed a massive breakthrough. Researchers developed an Artificial Intelligence (AI) model that could screen children for Attention-Deficit/Hyperactivity Disorder (ADHD) using nothing more than a simple retinal photograph. The study, which prospectively recruited children from Severance Hospital and Eunpyeong St. Mary’s Hospital, produced results that were staggering: the AI reportedly achieved an accuracy rate of  96.9%!

‍

In the world of medical testing, scientists use a metric called  AUROC  (Area Under the Receiver Operating Characteristic) to measure how well a test works.

• 0.5  means the test is no better than a coin flip (pure luck).
• 1.0  represents a perfect test with zero mistakes. 

‍

An AUROC of 96.9% is a near-perfect score, suggesting a tool is ready for immediate, real-world deployment. While headlines promised a revolution in mental health screening, a deeper look into this research and the study’s design has exposed that this 96.9% AUROC was more likely evidence of a flawed methodology rather than a biological reality.

‍

The Promise: How the AI "Sees" ADHD

To build their screening tool, researchers analyzed over 1,100 retinal images using a digital pipeline called AutoMorph and a machine-learning model known as XGBoost. The AI was trained to hunt for physical signals of the "Dopamine Connection." Dopamine is the primary neurotransmitter involved in ADHD, but it is also essential to the eye. It regulates synaptic formation, retinal blood flow, and vascular endothelial regulation. Because dopamine dysregulation influences how blood vessels grow and remodel, the study hypothesized that an ADHD brain would leave a unique "fingerprint" on the retinal vasculature, resulting in denser, thicker vessel structures.

On paper, the logic was sound: use AI to spot the subtle vascular remodeling caused by dopaminergic shifts. But a closer look at the investigation revealed that the AI wasn't just spotting ADHD; it was over-indexing on technical noise.

‍

Flaw #1: Batch Effects

The most significant "smoking gun" flagged by critics is a massive temporal mismatch. In other words, there was a severe disparity in the timeframes and conditions under which the retinal images for the two comparison groups were collected. For an AI to learn a biological condition, it must compare groups under identical technical conditions. Instead, this study created a time-traveling dataset:

• The ADHD Group:  323 children recruited prospectively in a tight 6-month window in  2022 .
• The Control Group:  323 children gathered retrospectively over a  17-year span  (2007 to 2024).This discrepancy triggers severe Batch Effects. This is a term scientists use to describe non-biological factors in an experiment that can cause inaccuracies in the data it produces. Fundus photography technology changed dramatically between 2007 and 2024. An investigation into the hardware uncovered shifts in camera models, lens optics, sensor degradation, and digital compression formats .Think of it this way: if you compare a selfie taken on the original 2007 iPhone with one from an iPhone 16, the AI doesn't need to look at your face to tell them apart; it just looks at the  2007 sensor noise  and pixel grain. The AI likely didn't learn to identify ADHD so much as it learned to distinguish between "old camera" and "new camera."

‍

Flaw #2: Control Group

A scientific study is only as reliable as its control group. The control in any experiment acts as a baseline against which the study group is compared. In this case, the control group should be composed of children without any neurodevelopmental disorders, or of “typically developing” children. 

In this study, the control group wasn't composed of healthy children from the community. Instead, they were patients visiting a tertiary ophthalmology clinic. Children visiting a specialist eye hospital are rarely "typical." They are there because they have symptomatic eye issues. This introduced a massive selection bias involving three major confounders:

• Refractive Errors (Myopia/Nearsightedness):  Severe myopia physically stretches the retina. This stretching alters vessel density and optic disc size, which were the exact markers the AI was examining.
• Strabismus:  Misaligned eyes.
• Ocular Anomalies:  Physical eye defects.Because these conditions directly alter retinal architecture, the AI likely learned to distinguish between "kids with ADHD" and "kids with severe eye problems," rather than "kids with ADHD" and "typical kids."

‍

Fatal Flaw #3: The "Mirror Image" Leakage

When training AI, you must never allow the "test questions" to leak into the "study material." The researchers, however, committed a fundamental violation of machine learning hygiene known as  Eye-to-Eye Data Leakage. The study split the data by the eye rather than by the participant. 

Human eyes are highly correlated; the left eye is a near-mirror of the right. If a child's left eye was used for training and their right eye was used for testing, the AI was effectively "cheating." Instead of learning the general traits of ADHD, the model was potentially memorizing individuals. This error artificially balloons accuracy metrics. 

‍

The True Test: Differential Diagnosis 

The true test of medical AI is diagnostic specificity, or differential diagnosis. This refers to the ability to tell one condition apart from another. While the model claimed 96.9% accuracy against a flawed control group, its performance collapsed when faced with real-world complexity.

When the researchers asked the AI to differentiate between ADHD and Autism Spectrum Disorder (ASD), the accuracy plummeted to a poor  63% AUROC. In real-world clinical settings, an accuracy of 63% is dangerously close to a 50% coin flip. Since ADHD frequently co-occurs with ASD, anxiety, or intellectual disabilities, an AI that cannot handle these "clinical differentials" is functionally useless in a doctor's office. The failure at this stage proves the model was likely detecting technical quirks of the dataset rather than a unique biological marker for ADHD.

‍

Conclusion:

To move from the lab to the clinic, we must establish a foundation built on rigor rather than high-speed data scraping. Moving forward, we must demand these 3 Pillars of Trusted Medical AI :

1. Prospective, Unified Hardware:  Data must be collected on identical camera systems with the same protocols to eliminate technical "batch effects."
2. Healthy, Community-Based Controls:  Comparisons must be made against truly "typically developing" children, not patients from eye clinics with their own retinal anomalies.
3. Rigorous External Validation:  AI models must be tested on independent datasets from entirely different hospital networks to ensure they aren't just "memorizing" one hospital's specific machinery.Artificial Intelligence holds immense potential, but we must demand detective-like scrutiny before these tools reach our children. In the search for the "window to the mind," we have to make sure we aren't just looking at a smudge on the glass.

‍

The dream of a quick eye scan to diagnose ADHD is not dead, but it must be rescued from "fast science" shortcuts and buzzy headlines. 

‍

Background:

One of the more persistent concerns among parents of children with ADHD is whether stimulant medications will stunt their child's growth. A large Israeli cohort study now offers some of the most rigorous reassurance to date, and its methodology sets it apart from earlier research. 

The question has long been complicated by a more fundamental uncertainty: do growth differences in children with ADHD stem from the condition itself, from stimulant treatment, or from factors present before any medication is ever prescribed? Without a clear answer, clinicians and families have faced a genuine dilemma when weighing the benefits of stimulant therapy against potential long-term physical costs. 

Most previous studies compounded this difficulty by comparing group-average heights, which ignores the crucial variable of genetic potential. A child who is short relative to the general population may simply have short parents. Failing to account for this introduces systematic bias and can make medications appear more harmful than they are. 

The Study:

The Israeli research team addressed this directly. Using health records from a nationwide provider, they assembled a retrospective cohort of children born between 1995 and 2003, following them through 2023. This amount of time was long enough for all participants to have reached adult stature (defined as 17 or older for females, 19 or older for males). Their sample included 5,671 children with untreated ADHD, 11,846 who received stimulant treatment, and 47,258 non-ADHD controls. Children who took stimulants for only one to two months, or who had chronic medical conditions requiring long-term medication, were excluded to avoid confounding the results. 

Crucially, adult height was evaluated not against population norms but against each individual's expected height, calculated from parental heights using the Tanner-Goldstein-Whitehouse method, a standard approach for estimating genetic height potential via mid-parental height. 

When the researchers compared adult heights across the three groups using analysis of variance (ANOVA), they did find statistically significant differences. But statistical significance, particularly in studies with tens of thousands of participants, does not automatically translate into clinical significance. The effect sizes were consistently very small, and the absolute differences were under one centimeter, which is a margin considered clinically negligible. 

Their conclusion is measured but clear: after accounting for genetic growth potential, neither an ADHD diagnosis nor stimulant treatment was associated with meaningful reductions in adult height. The findings, they argue, support prioritizing behavioral and functional outcomes when making treatment decisions, since the risk of clinically significant height loss appears to be minimal. 

The Take-Away:

For families navigating ADHD treatment, the practical implication is significant: concerns about permanent growth suppression, while understandable, should not be the primary driver of whether or how long a child receives stimulant therapy. 

‍

A recent meta-analysis examined how well cognitive behavioral therapy (CBT) improves not just symptoms, but everyday functioning and quality of life in adults with ADHD. ‍

‍

The Background:

ADHD in adults affects far more than attention or impulsivity. It often disrupts key areas of life: 

• Education: Adults with ADHD tend to have lower GPAs, use fewer effective study strategies, achieve less academically, and are more likely to drop out.  

• Work: They are more likely to experience job instability, including underperformance, unemployment, being fired, or frequent job changes.  

• Social life: They often report smaller social networks, fewer close relationships, greater loneliness, and difficulty maintaining friendships or intimacy. Importantly, stronger social networks can help buffer (reduce) the impact of ADHD symptoms on daily life.  

• Quality of life: Overall well-being is typically lower, affecting not only individuals but also their families and close relationships.

‍

These broad impacts highlight a key issue: reducing symptoms does not automatically translate into better day-to-day functioning. 

CBT is a structured, skills-based therapy that helps people: 

• Identify and challenge unhelpful thought patterns  

• Reduce avoidance behaviors  

• Build practical strategies for managing time, organization, and other executive functions (the mental skills used to plan, focus, and follow through)  

While both medication (especially stimulants) and CBT improve core ADHD symptoms, CBT is particularly aimed at improving real-world functioning. 

The Study:

The researchers analyzed studies involving adults diagnosed with ADHD (or showing clinically significant symptoms). They included: 

• Randomized controlled trials (RCTs): studies comparing CBT to another treatment or to no treatment  

• Within-subject studies: studies measuring change in the same individuals before and after CBT  

They focused specifically on outcomes beyond symptoms: 

• Occupational functioning (work performance)  

• Global functional impairment (overall daily functioning)  

• Social relationships  

• Academic functioning  

• Quality of life  

‍

The Results:

1.  Strongest Effects: Occupational functioning
CBT showed consistently strong improvements in work-related functioning compared to control groups, both immediately after treatment and at follow-up. This was the most robust finding across domains. 

2. Moderate Improvement: Global Functional Impairment
CBT led to moderate improvements in overall daily functioning, with some evidence that gains persist over time. In studies tracking individuals over time, improvements were even stronger at follow-up. 

3. Modest Gains: Social Relationships
CBT produced small to moderate improvements in social functioning. Benefits were present both after treatment and at follow-up, but were less pronounced than in work-related outcomes. 

4. Limited Effects: Academic Functioning
There were moderate short-term gains when CBT was compared to control groups, but these did not persist at follow-up. Within-subject studies showed only small improvements overall. 

5. Modest and Inconsistent Effects: Quality of Life
Improvements in quality of life were small when compared to control groups and often did not last. However, studies tracking individuals over time showed moderate improvements, suggesting some benefit that may not always show up clearly in between-group comparisons. 

Overall, the findings suggest: 

• CBT does improve real-world functioning, not just symptoms  

• The strongest and most consistent benefits are in occupational (work) functioning  

• Gains in social life, academics, and overall quality of life are more modest and variable  

• Improvements in functioning do not always track directly with symptom reduction  

One notable nuance: CBT did not always outperform other active treatments (like medication or other therapies). This suggests that while CBT is effective, its benefits may partly overlap with broader therapeutic or support effects rather than relying on a single, unique mechanism. 

The Take-Away: 

CBT is a valuable, evidence-based treatment for adults with ADHD, especially for improving work functioning and overall daily life management. However, its impact on relationships, academic outcomes, and quality of life is more limited and less consistent, pointing to the need for more targeted or combined approaches in those areas. 

‍

The Background:

ADHD and epilepsy are the two most common neurological disorders in children and adolescents. Additionally, they appear as co-diagnoses more often than chance would predict. Roughly a quarter of children with epilepsy also have ADHD, and children with ADHD face a 2.5-times greater risk of developing epilepsy than their peers. 

Clinicians have long suspected that carrying both diagnoses compounds cognitive difficulties, but no rigorous quantitative review has mapped out exactly how much, or in what ways. This new meta-analysis now fills that gap. 

The Study:

The team pooled data from peer-reviewed studies that included children and adolescents diagnosed with both conditions alongside at least one comparison group: children with neither condition, children with epilepsy alone, or children with ADHD alone. To capture the breadth of thinking skills, they constructed a general intelligence factor drawing on six cognitive domains: 

• Crystallized intelligence — accumulated knowledge and its application 

• Fluid reasoning — tackling novel problems through logical thinking 

• Working memory — holding and mentally manipulating information in the short term 

• Processing speed — executing simple or well-practiced mental tasks quickly 

• Reaction time — responding rapidly to basic stimuli 

• Long-term memory and fluency — efficiently storing and later retrieving new information 

The Results:

Across eleven studies (995 participants), children and adolescents with both conditions scored moderately lower on general intelligence than those with epilepsy alone. The same pattern held across all six cognitive domains. Seven studies (785 participants) comparing the dual-diagnosis group with those who had ADHD alone found an equally consistent moderate deficit, replicated in every domain. 

The clearest signal emerged when researchers compared children and adolescents carrying both diagnoses to typically-developing peers. Seven studies covering 427 individuals revealed a substantially larger gap in general intelligence, with the effects of the two conditions appearing to be roughly additive, meaning the combined burden was approximately equal to the sum of each condition's individual impact. This pattern held across five of the six domains. 

The Interpretation:

The results come with meaningful caveats. Variability across individual studies was moderate in the first two comparisons and high in the third, reflecting real differences in how studies were designed, which populations they sampled, and how they measured cognition. While there was no sign of publication bias in the first group, it was not assessed in two of the three analyses. 

The authors describe “a widespread profile of cognitive dysfunction” in children and adolescents with both epilepsy and ADHD, while underscoring that the substantial variability between studies warrants caution in drawing overly precise conclusions. The findings nonetheless carry practical weight: children managing both conditions may need more intensive cognitive screening and support than current clinical practice routinely provides. 

‍

The focus on children and adolescents with ADHD often revolves around behavioral issues and academic difficulties, but the social struggles are real. Around 60% of youth with ADHD experience meaningful difficulties in social skills, reading social cues, and forming reciprocal relationships with peers. Over time, these struggles can raise the risk of anxiety and depression. 

Medication remains the primary treatment for ADHD, with stimulants like methylphenidate (Ritalin) being the most commonly prescribed. While effective at reducing core symptoms such as inattention and impulsivity, medication has not been shown to improve social behavior or peer relationships.

The Background: 

Exercise has recently emerged as a promising adjunctive therapy. A newly published meta-analysis examined whether structured physical activity can specifically improve social functioning in young people with ADHD. It builds on a previous review from 2015, addressing gaps that earlier work left open: social outcomes were rarely treated as a primary focus, and no prior analysis had systematically compared exercise types or asked how much exercise is actually needed to see benefits. 

The Study: 

The analysis included 13 randomized controlled trials involving 703 participants aged 6 to 18, all clinically diagnosed with ADHD. Only exercise programs lasting at least four weeks were considered. Studies that combined exercise with other therapies, such as psychotherapy, were excluded to isolate exercise's specific effects. 

The researchers used a technique called network meta-analysis, which allows different interventions to be compared against one another even when they haven't been tested head-to-head, alongside dose-response modeling to identify how much exercise produces the greatest benefit. 

• Closed-skill exercise: takes place in stable, predictable environments where movements can be planned in advance  (such as in gymnastics, track and field, or strength training). 

• Open-skill exercise: unfolds in dynamic settings that demand constant adaptation  (team sports such as basketball or soccer, and those requiring specific hand-eye coordination such as table tennis). 

• Multicomponent exercise blends both: a session might begin with a structured, self-directed drill (closed-skill) before transitioning into reactive, opponent-driven play (open-skill). 

• Mind-body exercise integrates movement, mental focus, and controlled breathing (includes practices like yoga, tai chi, and qigong). 

Results: 

The most striking results came from closed-skill exercise: across four studies involving 92 participants, it was associated with a very large reduction in social dysfunction. Open-skill exercise, by contrast, showed no measurable improvement across four studies with 91 participants. Multicomponent exercise (the group combining elements of both open- and closed-skill) reported large gains in two smaller studies with 33 participants.  

Mind-body exercise showed a moderate benefit across three studies involving 44 participants. 

The dose-response analysis offered a practically useful finding: 30 to 60 minutes of moderate-intensity exercise per day appeared to produce the best outcomes, with a minimum of roughly 15 to 30 minutes daily needed to achieve any meaningful benefit. 

The Take-Away: 

The results are encouraging but should be interpreted carefully. The number of studies in each category was small (two to three studies each), and sample sizes were modest, meaning the findings may not hold up as more evidence accumulates. The absence of publication bias is reassuring, as is the use of rigorous methodology, but this remains an early-stage evidence base. Larger, well-designed trials are needed before firm clinical recommendations can be made. 

For now, the findings position structured physical activity  (particularly closed-skill and multicomponent exercise) as a plausible complement to existing ADHD treatment, specifically targeting the social difficulties that medication tends not to address. The practical dose guidance is a useful starting point: around half an hour of moderate daily exercise as a minimum, with an hour as the apparent sweet spot. As low-risk additions to a treatment plan go, that’s a relatively accessible bar for most families to consider alongside professional guidance. 

‍

Exercise has attracted growing attention as an intervention for ADHD. As a potential treatment option for ADHD, it is, of course, highly appealing because it can be low- to no-cost, widely accessible, and free of the side effects that can accompany medication. From previous studies, we know that certain types of exercise may be more effective than others, but do we actually know enough for clinicians to prescribe physical activity as a treatment for ADHD? 

The First Study: Effects on Core ADHD Symptoms 

Despite encouraging findings in individual studies, researchers have lacked clear guidance on which types of exercise work best, at what intensity, and for how long. A meta-analysis by Chen et al. set out to address this by pooling data from 20 randomized controlled trials (RCTs) involving 841 children and adolescents aged 4–18, all of which compared exercise interventions against non-exercising control groups. 

The results were cautiously optimistic. Across standardized symptom scales, exercise produced a small improvement in ADHD symptoms overall. Objective cognitive tests showed a moderate improvement. Emotional and behavioral outcomes, however, showed no significant change. 

To understand what was driving differences between studies, the researchers broke results down by exercise type. Therapeutic and alternative exercises (targeted movements and specific techniques such as those prescribed by physical therapists) were associated with moderate symptom improvements. Mind-body practices (such as yoga or tai chi) showed small-to-moderate gains. Conventional aerobic exercise yielded smaller effects, while skill-based competitive sports showed no measurable benefit. Notably, the variability between individual studies remained high throughout, meaning these categories should be interpreted with some caution. 

Results:

The authors recommend that clinicians and parents consider incorporating therapeutic or alternative exercise sessions twice a week, each lasting 60–90 minutes, as a supplemental strategy alongside existing ADHD treatment. They stop short of calling this definitive, noting that future research should clarify how exercise produces its effects and how it might best be combined with medication or behavioral therapy. 

The Second Study: Effects on Inhibitory Control 

A second meta-analysis, by Zhang et al., zoomed in on a specific and particularly relevant cognitive challenge in ADHD: inhibitory control. Inhibitory control refers to the ability to suppress impulsive responses and tune out irrelevant distractions. This capacity underlies much of the restlessness, interrupting, and difficulty staying on task that characterize the condition. 

This analysis drew on 34 studies with over 1,300 participants spanning all age groups, making it broader in scope than the Chen et al. review. Overall, exercise was associated with a moderate improvement in inhibitory control. When the analysis was restricted to RCTs alone, this finding held up. When studies with a high risk of bias were excluded, however, the effect size dropped to small-to-moderate. 

One notable null result: three studies that used EEG to measure brain activity during inhibitory tasks found no significant effects on the neural signatures most closely tied to this process. This suggests exercise may influence behavior without necessarily changing the underlying brain mechanisms researchers expected, or that current methods aren't yet sensitive enough to detect such changes. 

The dosing question produced some of the more practically useful findings. Single exercise sessions yielded only borderline small improvements. Sustained exercise programs, by contrast, showed moderate improvements, and programs with sessions three times per week produced large gains and had the strongest effect between the two meta-analyses. Exercise intensity and total program duration, perhaps interestingly, were not significant factors. 

Results: 

The authors are measured in their conclusions: exercise shows a real but modest benefit for inhibitory control, and frequency appears to matter more than intensity. They caution against overstating the case for exercise as treatment for ADHD overall, as it did not significantly affect hyperactivity or impulsivity as standalone outcomes, and its neural effects remain unclear. 

The Broader Picture : 

Ultimately, these two meta-analyses support exercise as a meaningful supplemental intervention for ADHD, particularly for attention and cognitive control, while urging realistic expectations. Neither suggests exercise should replace established treatments. Both are limited by high variability across the underlying studies, and both call for better-designed research to sharpen the guidance available to clinicians and families. 

‍

Boredom is more than just feeling restless or under-stimulated. It’s a negative emotional state that arises when activities feel meaningless or dull and, for those with ADHD, this negative emotional state might be markedly more intense. Researchers increasingly view boredom as functional: an internal signal pushing people to seek more rewarding and meaningful experiences. But for some, that signal becomes chronic and overwhelming.

People who are highly prone to boredom face a range of psychological and behavioral consequences, including anxiety, depression, difficulty identifying their own emotions (alexithymia), impulsivity, and physical complaints. These struggles often surface in harmful behaviors: overeating, substance use, compulsive internet use, and gambling.

For people with ADHD, boredom can cross into genuine distress. Many describe it as “torture” or “an itchy coat you can’t scratch”,  language that conveys not mild discomfort but an urgent, almost unbearable need to escape. This makes sense given that ADHD involves core difficulties with attention, arousal regulation, and motivation, all of which make sustained engagement harder and boredom far more likely.

The Study:

A recent meta-analysis of 18 studies involving more than 22,000 participants confirmed a moderately strong and consistent positive association (an overall effect size of r = 0.40) between ADHD and self-reported boredom. All but one study found significant results, and there was no evidence of publication bias.

“While the relationship between ADHD and boredom may seem obvious,” the authors state, “this has paradoxically led to the phenomenon being understudied.”

Despite how significant this connection appears to be, the researchers noted it has attracted surprisingly little scientific attention; a gap they attribute to a widespread assumption that boredom in ADHD is simply a byproduct of inattention or impulsivity, and therefore not worth studying on its own terms. They push back on that view, arguing that boredom may be a more fundamental part of the ADHD experience: a bridge between atypical brain function and the behavioral, emotional, and cognitive difficulties that shape long-term outcomes.

The Take-Away: 

Ultimately, addressing the profound boredom experienced by individuals with ADHD requires a multifaceted approach that goes beyond simply treating inattention. Researchers emphasize the need for rigorous studies to determine if stimulant medications actively reduce this intense boredom by repairing underlying brain mechanisms, rather than just as a side effect of improved focus. Beyond medication, tailored psychological therapies may offer promise; psychoeducation can help individuals reframe boredom as a biological signal rather than a personal failure or character flaw. 

Additionally, another approach suggests that rather than solely focusing on treating the individual, systemic issues must be addressed, such as the effects of low-stimulation environments. For example, prioritizing a better "person-environment fit" through smaller class sizes, flexible academic pacing, and/or offering highly stimulating, novel tasks, schools and workplaces can offer meaningful relief from the chronic distress of ADHD-related boredom. 

A new study from Japan suggests that infants born with craniosynostosis are significantly more likely to be diagnosed with ADHD later in childhood. Craniosynostosis is a condition in which the bony plates of the skull fuse prematurely, leading to increased intracranial pressure. 

The Background:

Craniosynostosis affects roughly one in every 2,000 births. When the skull’s natural seams close prematurely, it can restrict brain growth and increase intracranial pressure, potentially reducing blood flow to the brain. Because the condition is relatively rare, it has been difficult to study at scale until now. 

The Study:

To overcome this, researchers tapped into a large Japanese insurance database compiled by JMDC, Inc., which holds records on around 20 million people, or about 15% of Japan’s population. Drawing on two decades of data, the team tracked over 338,000 mother-child pairs. Children with related genetic syndromes or chromosomal conditions such as Down syndrome were excluded to keep the focus on craniosynostosis itself. 

Of the children studied, around 1,145 had craniosynostosis, and 7,325 were diagnosed with ADHD. After accounting for factors like sex, birth year, maternal age, mental health history, pregnancy infections, and birth complications, children with craniosynostosis were found to have roughly 2.4 times the risk of a subsequent ADHD diagnosis compared to those without it. 

To test whether shared family genetics or home environment might be driving the association rather than the skull condition itself, the researchers conducted a separate analysis among siblings. The elevated risk remained at 2.2 times. The consistency of the finding across both analyses strengthens the case for a genuine biological link. 

The Results:

The results point to raised intracranial pressure and restricted cerebral blood flow as plausible mechanisms, though the study’s observational design means causation cannot be confirmed. Ultimately, these findings highlight the need for proactive, long-term care strategies for those born with craniosynostosis. By establishing a solid link between premature skull fusion and a significantly higher risk of ADHD, the research demonstrates that medical care for this condition should not end once the skull's physical structure is addressed.

The Takeaway:

Pediatricians, neurologists, and parents can use this data to implement early, routine behavioral and developmental screening for these children as they grow. This additional support would ensure that those who do develop ADHD can receive timely interventions, educational aids, and therapies, ultimately improving their long-term developmental outcomes.

Children and adolescents with ADHD come into contact with child welfare services (CWS) far more often than their peers. There are many contributing factors to consider, including the fact that hyperactivity and impulsivity frequently lead to behaviors that are considered disruptive and cause academic and social difficulties. Many of these children are also growing up in households marked by parental conflict and/or single-parent arrangements.  All of these circumstances can compound vulnerability and, historically, increase the likelihood of CWS involvement.

Background: 

In Norway, Child Welfare Services operate at the municipal level and are legally required in every local authority. Their scope spans investigation, family support, and, where necessary, out-of-home placement and ongoing monitoring. Grounds for intervention include abuse, neglect, behavioral or psychosocial difficulties, and inadequate care-giving. Norwegian CWS works closely with health, education, and social services and places a strong emphasis on keeping families together. Compared with systems in countries such as the United States, Poland, Romania, and the Czech Republic, the Norwegian approach sets a lower bar for intervention and leans toward home-based support, while setting a higher bar for out-of-home placements. This model is shared by other Nordic countries, as well as Germany and the United Kingdom. 

Research into whether ADHD medication affects child welfare caseloads is remarkably sparse. A single Danish study previously found that medication treatment accounted for much of an observed decline in foster care cases, but no study had examined medication’s broader impact on CWS involvement, covering both supportive interventions and out-of-home placements. 

Norway’s universal single-payer health system and comprehensive national registers make population-wide research of this kind feasible. Drawing on these resources, a Norwegian research team set out to test whether ADHD medication reduces children’s contact with CWS and their need for out-of-home placement. 

The Study:

This study included all 5,930 children and adolescents aged 5 to 14 who received a clinical ADHD diagnosis from Child and Adolescent Mental Health Services between 2009 and 2011. Each was followed for up to 4 years post-diagnosis, the upper age limit being 18, at which point CWS jurisdiction ends. This group was compared with more than 53,000 peers who had no CWS contact during the same period. 

The results showed a meaningful, though not dramatic, association between medication and reduced CWS contact. At one year, treated children had approximately 7% fewer contacts with CWS; by two years, that figure had risen to around 12%. The effect then narrowed, settling at roughly 7–8% reductions at the three- and four-year marks. 

The picture for out-of-home placements is considerably less convincing. The research team highlighted a 3% reduction at two-year follow-up, but this finding barely crossed the threshold of statistical significance, and no effect was observed at the one-, three-, or four-year follow-up points. 

The Take-Away:

The authors concluded that pharmacological treatment for ADHD is associated with reductions in both supportive CWS services and out-of-home placements among children affected by clinicians’ prescribing decisions in Norway. A more cautious reading of the same data, however, would emphasize an overall reduction in CWS contact of roughly 8%, while treating the out-of-home placement finding as, at best, inconclusive. 

‍